A recent article in the Wall Street Journal summarizes how Pfizer is targeting use of a new cancer drug to patients with a particular genetic anomaly. Are you listening, pharmacists? This is an opportunity for us! I’ve written about this before, as I believe we’re the ones who can help patients understand the implications for them, and we can, through developing systems, help find patients who will be candidates for certain drug therapies. In late November, APhA, together with several other pharmacy organizations, will be working with the National Institutes of Health on strategies for pharmacy education in genomics. The long-term implications for our profession are huge. I would welcome your thoughts on the topic.